RightRep EN · PT Open the app
BLOG

Can You Train With Jumper's Knee? The Volume Audit: Where Lian's Census of 613 Elite Athletes Counted Jumper's Knee in 14.2% of Them — 44.6% of Volleyball Players, 31.9% of Basketball Players, Zero in Cycling and Orienteering — With Symptoms Already Averaging 32 Months and a Function Score of 64 Out of 100; Where Blazina Named the Condition in 1973 and Cook and Purdam's Continuum Explained Why 'Inflammation' Is the Wrong Word and Rest the Wrong Tool; Where Visnes's In-Season Randomized Trial Watched 12 Weeks of Decline-Board Eccentrics Buy Nothing (VISA 71.1 to 70.2 Against Control 76.4 to 75.4) While van Ark's Isometric-Isotonic Trial Cut Pain in Four Weeks Without Touching a Minute of Match Volume and Rio's Isometric Bout Dropped Pain From 7.0 to 0.17 for at Least 45 Minutes While Adding 18.7% to Quadriceps Strength; Where Purdam's 25-Degree Decline Pilot Fell From VAS 74.2 to 28.5 While the Flat-Footed Squat Did Nothing; Where Kongsgaard's Three-Arm Trial Caught the Cortisone Bait-and-Switch — the Injection's Good Six Weeks Decaying by Month Six Against Heavy Slow Resistance, the Most Satisfied Arm with Elevated Collagen Turnover — and Liu's 2026 Network Meta-Analysis of 17 Trials Ruled Nothing Superior to HSR; Where Fredberg's Preseason Scans Flagged Abnormalities in 18% of Silent Patellar Tendons of Which Only 17% Ever Became Symptomatic, Mendonça's Alignment File Priced Tight Iliotibial Bands at Prevalence Ratio 5.26, and Bittencourt's 1,553 Young Brazilians Made the Patellar Tendon 79% of All Lower-Limb Tendinopathies: the Tendon's Medicine Is the Same Load That Broke It, Re-Dosed on the Tendon's Clock, Not the Calendar's

By RightRep AI Assistant · · 20 min read

There is a fence at the top of this post and it outranks everything below it: knee pain in an athlete who is still growing, sitting exactly on the tibial tuberosity bump (Osgood-Schlatter) or at the bottom tip of the kneecap's growth plate (Sinding-Larsen-Johansson), is a different, age-specific file — an apophysitis of immature bone, not this one — and it gets a clinician's assessment, not a loading program. The second fence: a pop in the front of the knee during a jump or landing followed by the sudden inability to straighten the leg or lift it against gravity is a suspected patellar-tendon rupture — an emergency room today, not a programming question. The third fence: diffuse joint swelling, locking, giving way, night pain, fever or illness-shaped symptoms belong to a clinician this week; this post is about one specific, focal, load-driven ache at the tendon's attachment that the athlete can point to with one finger. And one honesty clause that outranks both internet camps: this is a load-management file, not a cure passport — the tendon's medicine is the same load that broke it, re-dosed, and the numbers below are what happens when the dose is respected, not what rest, braces or wishful thinking buy. With the fences respected, the question underneath is the one every squat rack and volleyball court already knows: the resting script ("stop jumping, stop squatting, wait") versus the grind script ("no pain no gain, tape it up"). The evidence contradicts both — in opposite directions, and mostly in public since 2004.

The short answer: train — but the program runs on the tendon's dose meter, not the calendar

Strip the file to its spine. The diagnosis is load arithmetic: in the elite census of 613 athletes across nine sports, jumper's knee lived in 14.2% of them — 44.6% of volleyball players and 31.9% of basketball players, against zero cases in cycling and orienteering — because the patellar tendon fails on stored-and-released energy (jumping, sprinting, deep knee bends), not on mileage [2]. Rest is the wrong tool: the continuum model that now runs the field reads tendinopathy as a load-response state — reactive, dysrepair, degenerative — not an inflammation to be iced into silence, which is why the symptoms in that same elite census had already lasted 32 months on average [6][2]. The in-season paradox is the file's sharpest edge: 12 weeks of decline-board eccentric squats during the competitive season bought elite volleyball players literally nothing (function score 71.1 to 70.2, control 76.4 to 75.4), because you cannot out-exercise a load you are still standing in [9] — while four weeks of isometric and isotonic holds cut pain significantly without touching one minute of training or match volume [12], and a single isometric bout dropped pain during a decline squat from 7.0 to 0.17 for at least 45 minutes while adding 18.7% to quadriceps strength [11]. The off-season door is where the cure file lives: the 25-degree decline-board pilot took pain from VAS 74.2 to 28.5 [10], and the three-arm trial that put cortisone, eccentrics and heavy slow resistance head-to-head watched the injection's good six weeks decay by month six while the heavy slow resistance arm ended the most satisfied, with measurably remade tendon collagen turnover [13]. And the 2026 verdict across 17 randomized trials: nothing beats heavy slow resistance — no exercise hierarchy, HSR the reference treatment [14]. Train the whole body, treat the tendon's dose as the variable, and let the pain-with-load trend — not the calendar — steer the volume.

Who is asking: the scale file

This is the most common tendon problem in jumping sport, and the censuses agree across every level. The elite file: 613 Norwegian national-level athletes examined across nine sports — current jumper's knee in 14.2% (87 athletes), another 8% with previous symptoms, 44.6% of male volleyball players and 31.9% of basketball players against zero in cycling and orienteering; men at 13.5% against women at 5.6%; and among the current cases the symptoms had run 32±25 months with a function score of 64 out of 100 [2]. The non-elite file: 891 Dutch athletes from seven popular sports — 8.5% overall, volleyball again highest at 14.4% against soccer's 2.5%, men 10.2% against women 6.4%, symptoms averaging 18.9 months [3]. The soccer file: 51 European elite clubs and 2,229 players followed across eight seasons — 137 patellar tendinopathies, 1.5% of all injuries, 0.12 cases per 1,000 hours, 2.4% of players affected each season, 61% of episodes costing a week or less of absence — and 20% of them recurrences [4]. And the Brazilian youth file, the anchor this library carries for its own audience: 1,553 athletes (mean age 14.1) across volleyball, basketball, judo, gymnastics, tennis and futsal followed through the 2015–2017 seasons of one club — 100 lower-limb tendinopathies recorded, and the patellar tendon was 79% of them; male volleyball players carried 41%, male basketball players 25%, female volleyball players 13%; incidence ran 2.5, then 4.2, then 2.1 per 1,000 hours [5]. The gym translation is direct: the reader with a focal ache under one kneecap is not an outlier — in the jump-and-squat sports this is one in two to one in eight of their training partners, most of them mid-career, most of them months deep before they ever ask the question.

What jumper's knee actually is: the naming and continuum file

The name is older than most of its sufferers: Blazina and colleagues described "jumper's knee" in 1973 from the practice of four surgeons watching the same focal pain at the patellar tendon's attachment travel through the athletes of Los Angeles — staged then, as now, by how long pain persists after activity [1]. What it is not is an inflammation, and the field spent twenty years paying for that word: the continuum model — reactive tendinopathy in the young overloaded tendon (a reversible, cell-driven response to an acute spike), tendon dysrepair (the attempted-healing state), and degenerative tendinopathy (the long-standing, structurally changed tendon of the multi-year case) — replaced "tendinitis" precisely because anti-inflammatory tools kept failing against a load problem [6]. Two consequences run the whole file: the stage decides the dose — the reactive tendon of a 19-year-old mid-season needs volume reduction first, while the degenerative tendon of a 32-year-old needs load restoration — and rest is not a treatment at any stage: unloaded tendons lose the very collagen synthesis that remodeling runs on, which is why the two internet scripts (total rest, and total grind) produce the same long-suffering patient [6]. The mechanism is energy, not force alone: the patellar tendon stores and releases enormous loads in jumping and landing — multiples of body weight per hop — which is why the census's sport gradient runs volleyball-basketball-soccer-cycling and zero [2][6].

The scan-honesty door: what the picture does and does not entitle anyone to

The imaging file humbles both the scanner and the scared. In the longitudinal ultrasound study of 54 elite Danish soccer players scanned before and after a season, 18% of patellar tendons showed abnormalities in players with no symptoms whatsoever at the preseason scan — and only 17% of those abnormal-but-silent tendons became symptomatic jumper's knee within the season (the Achilles tendons told the same story: 11% abnormal, low conversion) [7]. Read that arithmetic honestly and it cuts twice: a scan finding is not a diagnosis of destiny — more than four of five structurally abnormal tendons stayed silent through a full professional season [7] — and by the same token a clean scan does not erase load pain; the diagnosis that runs this file is the focal load-driven ache on examination, with imaging as context, not verdict. The practical rule the family posts keep re-learning (the meniscus tenant audit, the disc tenant audit, the ACL ligament audit): the picture names the tenant, the training question is still about the load.

The biomechanics door: the whole limb writes the tendon's dose

Why one athlete's tendon fails on a volume a teammate absorbs is not character — it is mechanics, and the alignment file prices it. In the Brazilian cross-sectional study of 31 male basketball and volleyball athletes, athletes with reduced iliotibial-band flexibility carried patellar-tendon abnormalities at a prevalence ratio of 5.26, and those with shank-forefoot alignment beyond the 24-degree cutoff at 4.42 — tight lateral chain and a turned-in forefoot both funneling load toward the same square centimeter of tendon [8]. The lifting translation: the patellar tendon's dose is written by the whole limb — ankle range, hip abduction, lateral-line mobility — which makes the warm-up ramp and the accessory work (hip mobility, calf and tibialis work, single-leg strength) part of the tendon's program, not decoration around it. It also retires the fatalism: these are modifiable in a weight room, on a clock of weeks, without touching sport technique.

The in-season paradox: the trial that bought nothing, and the trials that bought pain relief for free

Here is the finding that separates this file from every "do your eccentrics" pamphlet ever printed. Visnes and colleagues randomized 29 elite volleyball players with patellar tendinopathy to 12 weeks of decline-board eccentric squats — the very protocol this condition is famous for — during the competitive season: the function score went 71.1 to 70.2 in the training group against 76.4 to 75.4 in the controls. Nothing. No change at 12 weeks, none at the follow-ups [9]. The lesson is dose arithmetic, not futility: the eccentric protocols were built for the off-season, on tendons whose jump volume had been removed; pile the program on top of an unchanged match load and the spike the tendon was already failing on stays in the equation [9]. Now the counter-file, because the paradox has a resolution: van Ark's randomized trial gave in-season jumping athletes (playing at least three times a week) four weeks of isometric or isotonic quad work — both arms cut pain significantly (P=0.012 and P=0.003, effect r=−0.63 in each) with zero modification of training and competition load — the first demonstration that the tendon's pain can be treated in-season without touching the sport [12]. And Rio's crossover trial explains why the type of contraction matters mid-season: a single bout of isometric contractions dropped decline-squat pain from 7.0 to 0.17 (isotonic managed 6.33 to 3.75, P<0.001), the analgesia held for at least 45 minutes, and quadriceps strength was 18.7% higher afterward — the isometric bout is both the painkiller and the warm-up [11]. The in-season formula writes itself: keep playing, add the holds, save the heavy rebuilding for the block where jump volume can actually drop [9][11][12].

The analgesia door: the 45-minute file and the predictor inside it

The isometric file deserves its own door because it changed in-season management more than any injection ever did. The laboratory crossover: six volleyball players with patellar tendinopathy, one isometric bout — pain during the single-leg decline squat fell from 7.0 to 0.17, stayed down at the 45-minute retest, maximal quadriceps contraction rose 18.7%, and the cortical inhibition surrounding the painful tendon released measurably — pain relief without strength cost, in a sport where "manage the pain" used to mean "play weaker" [11]. The in-season randomized confirmation: 20 jumping athletes, four weeks, isometric leg-extension holds at 60 degrees of knee flexion (80% of maximal voluntary contraction) against isotonic leg extensions at 80% of an 8-rep max — the isometric arm produced significantly greater immediate analgesia at every session (P<0.002), and — the sleeper number — the size of the week-one analgesic response predicted the four-week function-score improvement (r=0.64) [16]. That correlation is the file's built-in steering wheel: the athlete who feels the holds work in week one is the athlete whose tendon is responding, and the one who does not is the one whose program needs the modified-block door instead [16].

The loading door: the decline board, the three-arm trial, and the 2026 verdict

When the calendar opens — off-season, or a block where jump volume can genuinely fall — the rebuilding file is the deepest in sports medicine. The decline board earned its fame in the pilot that started the protocol era: 17 chronic patients (pain over six months), 12 weeks of eccentric squats twice daily — the 25-degree decline-board group fell from VAS 74.2 to 28.5 (P=0.004) with six of eight patients back at sport, while the matched flat-footed squat group went 79.0 to 72.3 (P=0.144) with one return; at 15 months the decline group still held a mean VAS of 26.2 [10]. The tilt is the mechanism: 25 degrees of decline shifts the load to the knee extensor mechanism and the tendon's own attachment — the exercise is a dose, not a ritual [10]. Then the trial that reframed the whole menu: 39 men randomized for 12 weeks to peritendinous corticosteroid injections, eccentric decline squats, or heavy slow resistance — all three arms improved at 12 weeks; at the six-month follow-up the injection arm had deteriorated while the eccentric and HSR arms held their gains; the HSR arm ended the most satisfied, with tendon swelling down 12%, vascularization down 45%, and elevated collagen-network turnover — biochemically measured remodeling under load [13]. And the current verdict across the field: the 2026 network meta-analysis of 17 randomized trials — no exercise intervention superior to heavy slow resistance for short-term function gains, no clinically meaningful hierarchy among progressive loading strategies, HSR the reasonable reference treatment [14]. Heavy slow resistance, for the uninitiated, is exactly what a lifter already speaks: 3–5 sets of slow-tempo squats and leg presses, loaded progressively, three times a week, for twelve-plus weeks — the progressive overload logic applied to the tendon itself [13][14].

The injection door told honestly: the six-week king and the six-month bill

The cortisone file repeats itself across every tendon in the body — the elbow's version made it to a Lancet trial — and the patellar tendon's own three-arm data prices it cleanly: the injection arm's short-term improvement was real, and by the six-month follow-up it had decayed while both exercise arms held [13]. Nothing in this file says injections are useless — for the tendon that cannot start a program for pain, a clinician-delivered injection can be the on-ramp; nothing in it supports injections as the plan, either, because the plan's end-state (a remodeled, load-tolerant tendon) is only reachable through the loading door [13][14]. The injection decision belongs to a clinician who has examined the knee — which fence stands at the top of this post and repeats here at the door.

The props and the gear door: what the sleeve is and is not

No brace, tape, strap or sleeve appears anywhere in the trial file above, and that absence is the finding: the patellar tendon's variables that trials have moved are contraction type, tempo, load and volume — not compression gear. A knee sleeve buys warmth, proprioception and confidence, and confidence is not nothing in a pain file; but the reader who sleeves up to keep the same jump volume the tendon already failed on has bought a subscription to the recurrence row of the soccer census (20% of cases) [4]. The strap question answers the same way the arthritis file answers its braces: wear it if it helps you train, program as if it changes nothing.

So what do you actually do? The practical file

Six rules, every one sourced from the files above:

  1. Name the file before you load it. Focal, one-finger pain at the bottom pole of the kneecap with jumps, squats and deep knee bends is the jumper's knee file — the growing athlete's bump, the pop with a leg that will not straighten, and the swollen/locking/systemic knee are all different doors (the fences at the top of this post) [1].
  2. Do not rest it into weakness. The continuum file is unambiguous: load modulates the tendon's remodeling machinery, and the untreated course runs 32 months in elites [6][2].
  3. In-season, add the holds; do not touch the sport. Isometric holds for analgesia before sessions (pain 7.0 to 0.17 for 45 minutes, strength up 18.7%) plus isotonic maintenance — four weeks of that cut pain with zero change to training volume [11][12][16].
  4. When the calendar opens, run the block. Progressive heavy slow resistance is the reference treatment nothing has beaten; the 25-degree decline board is the alternative door with the pilot file behind it — either way, twelve-plus weeks of staged load management, logged like any tracked mesocycle [10][13][14][15].
  5. Audit the dose that caused it. Jump, sprint and squat volume and their spikes — not the tendon's existence — wrote the injury; the sport gradient (volleyball 44.6%, cycling zero) is the dose-response curve in the wild, and the alignment file (ITB flexibility PR 5.26) makes the lateral chain part of the fix [2][8].
  6. Track pain-with-load as a metric, not a mood. The function score this whole file runs on (VISA-P, 0–100) is a weekly number; the week-one analgesic response predicting the four-week gain (r=0.64) means the trend tells you which door you are in [16].

How RightRep fits into this

The jumper's knee file is, at its core, a counted-volume and load-trend question — and it is unanswerable without a record:

  • The volume ledger. The dose meter this entire file runs on — jumps, squat sets, loaded reps per session per week — is exactly what counted, scored sessions produce; the spike that caused the tendon's complaint is visible in the log before it is visible in the knee [2][9].
  • Camera-scored depth and tempo. The patellar tendon's per-rep dose is written by squat depth, speed and bounce; rep-by-rep scoring on squats, hinges and step-ups keeps the "re-dose" honest — heavy slow resistance is literally a tempo prescription [13].
  • The pain-with-load curve. A dated pain note beside the logged work turns "it feels worse lately" into the trend the whole steering logic (rule 6) runs on — the same 0–100 logic the trials used [11][16].
  • The whole body stays in the program. Upper body, posterior chain, the healthy leg, the single-leg accessory work that rebuilds the alignment file — none of it waits for the tendon [8].

The bottom line

  • The scale: 14.2% of 613 elite athletes (volleyball 44.6%, basketball 31.9%, cycling zero), 8.5% of 891 non-elite, 2.4% of elite soccer players per season with 20% recurrence, and 79% of all lower-limb tendinopathies in 1,553 young Brazilians were the patellar tendon [2][3][4][5].
  • The untreated course: symptoms averaging 32 months in elites, 18.9 months in non-elites, function at 64/100 — rest is not a treatment [2][3][6].
  • The in-season paradox: 12 weeks of decline-board eccentrics mid-season bought nothing (71.1 to 70.2 against 76.4 to 75.4) — you cannot out-exercise a load you are still standing in [9].
  • The analgesia door: isometric bout pain 7.0 to 0.17 for ≥45 minutes with strength +18.7%; four weeks of isometric/isotonic work cut pain (r=−0.63) with zero change to match volume [11][12].
  • The predictor: week-one analgesic response correlated with four-week function gains at r=0.64 — the trend is the steering wheel [16].
  • The loading door: decline board VAS 74.2 to 28.5 (flat-foot squat null); heavy slow resistance the most satisfied arm at six months with remodeled collagen turnover; the injection arm's gains decayed [10][13].
  • The 2026 verdict: across 17 randomized trials, nothing superior to HSR, no clinically meaningful hierarchy — HSR the reference treatment [14].
  • The scan honesty: 18% of silent elite patellar tendons were structurally abnormal; only 17% of them became symptomatic in a season — the picture does not write the program [7].
  • The mechanics: tight ITB PR 5.26 and shank-forefoot alignment PR 4.42 — the limb, not just the knee, writes the dose [8].

Train the whole body, dose the tendon like the load-responding tissue it is, let the pain-with-load trend steer — and let the camera keep the reps and the volume honest at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Blazina ME, Kerlan RK, Jobe FW, Carter VS, Carlson GJ. Jumper's knee. Orthopedic Clinics of North America, 1973;4(3):665–678. pubmed.ncbi.nlm.nih.gov
  2. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. American Journal of Sports Medicine, 2005;33(4):561–567. pubmed.ncbi.nlm.nih.gov
  3. Zwerver J, Bredeweg SW, van den Akker-Scheek I. Prevalence of jumper's knee among nonelite athletes from different sports: a cross-sectional survey. American Journal of Sports Medicine, 2011;39(9):1984–1988. pubmed.ncbi.nlm.nih.gov
  4. Hägglund M, Zwerver J, Ekstrand J. Epidemiology of patellar tendinopathy in elite male soccer players. American Journal of Sports Medicine, 2011;39(9):1906–1911. pubmed.ncbi.nlm.nih.gov
  5. Bittencourt NF, Vaz R, Garcia L, Zwerver J, Mendonça LD. Incidence of lower limb tendinopathy: a 3-year prospective study of youth elite athletes in a Brazilian sport club. Journal of Bodywork and Movement Therapies, 2024;40:461–464. pubmed.ncbi.nlm.nih.gov
  6. Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. British Journal of Sports Medicine, 2009;43(6):409–416. pubmed.ncbi.nlm.nih.gov
  7. Fredberg U, Bolvig L. Significance of ultrasonographically detected asymptomatic tendinosis in the patellar and achilles tendons of elite soccer players: a longitudinal study. American Journal of Sports Medicine, 2002;30(4):488–491. pubmed.ncbi.nlm.nih.gov
  8. Mendonça LD, Verhagen E, Bittencourt NF, Gonçalves GG, Ocarino JM, Fonseca ST. Factors associated with the presence of patellar tendon abnormalities in male athletes. Journal of Science and Medicine in Sport, 2016;19(5):389–394. pubmed.ncbi.nlm.nih.gov
  9. Visnes H, Hoksrud A, Cook J, Bahr R. No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clinical Journal of Sport Medicine, 2005;15(4):227–234. pubmed.ncbi.nlm.nih.gov
  10. Purdam CR, Jonsson P, Alfredson H, Lorentzon R, Cook JL, Khan KM. A pilot study of the eccentric decline squat in the management of painful chronic patellar tendinopathy. British Journal of Sports Medicine, 2004;38(4):395–397. pubmed.ncbi.nlm.nih.gov
  11. Rio E, Kidgell D, Purdam C, Gaida J, Moseley GL, Pearce AJ, Cook J. Isometric exercise induces analgesia and reduces inhibition in patellar tendinopathy. British Journal of Sports Medicine, 2015;49(19):1277–1283. pubmed.ncbi.nlm.nih.gov
  12. van Ark M, Cook JL, Docking SI, Zwerver J, Gaida JE, van den Akker-Scheek I, Rio E. Do isometric and isotonic exercise programs reduce pain in athletes with patellar tendinopathy in-season? A randomised clinical trial. Journal of Science and Medicine in Sport, 2016;19(9):702–706. pubmed.ncbi.nlm.nih.gov
  13. Kongsgaard M, Kovanen V, Aagaard P, Doessing S, Hansen P, Laursen AH, Kaldau NC, Kjaer M, Magnusson SP. Corticosteroid injections, eccentric decline squat training and heavy slow resistance training in patellar tendinopathy. Scandinavian Journal of Medicine and Science in Sports, 2009;19(6):790–802. pubmed.ncbi.nlm.nih.gov
  14. Liu Y, Li C, Yang F. Comparative effectiveness of exercise interventions for patellar tendinopathy: a systematic review and network meta-analysis of randomized controlled trials. BMC Sports Science, Medicine and Rehabilitation, 2026;18(1):296. pubmed.ncbi.nlm.nih.gov
  15. Malliaras P, Cook J, Purdam C, Rio E. Patellar tendinopathy: clinical diagnosis, load management, and advice for challenging case presentations. Journal of Orthopaedic and Sports Physical Therapy, 2015;45(11):887–898. pubmed.ncbi.nlm.nih.gov
  16. Rio E, van Ark M, Docking S, Moseley GL, Kidgell D, Gaida JE, van den Akker-Scheek I, Zwerver J, Cook J. Isometric contractions are more analgesic than isotonic contractions for patellar tendon pain: an in-season randomized clinical trial. Clinical Journal of Sport Medicine, 2017;27(3):253–259. pubmed.ncbi.nlm.nih.gov